Treatment Information

Back

Liver Cancer treatment details. Biologic therapy.

Memorial Sloan-Kettering Cancer Center, New York, NY, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:New York, NY
Treatments:Biologic therapyHospital:Memorial Sloan-Kettering Cancer Center
Drugs:Journal:Link
Date:Feb 2014

Description:

Patients:
This phase 2 study involved 24 advanced hepatocellular carcinoma patients. The median patient age was 67.5 years and 83% were male.

Treatment:
Patients received biologic therapy with cixutumumab, which is a monoclonal antibody to the IGF-1R protein that inhibits cancer cell growth.

Toxicities:
There was one treatment-related death due to kidney failure. Grade 3 high blood glucose and grade 3-4 liver toxicities were also reported.

Results:
The median overall survival was 8 months.

Support:
This study was partially supported by ImClone Systems, makers of cixutumumab.

Correspondence: Dr. Ghassan K. Abou-Alfa; email: [email protected]



Back